We acknowledge the pioneering work on the therapeutic value of glitazones in nonalcoholic steatohepatitis by Cusi, Harrison, Schenker, and their coworkers. We thank them for the correction related to the inclusion criteria of Belfort et al.'s study,1 and we apologize to the readers for this error in our article.2 We welcome the additional information on the calculation of the combined necroinflammation score. This information, though clearly relevant, does not appear in the online or print edition of the article, which simply refers to the Kleiner classification with no further detail. Critical details of the methodology or results should not be omitted despite the inevitable space constraints still invoked by journals in the digital era. We look forward to seeing the results of their ongoing studies, and we anticipate that the metabolic studies undertaken by them will continue to shed light on the pathogenesis of nonalcoholic steatohepatitis and potential treatment options.
Vlad Ratziu M.D.*, Stephen Caldwell M.D., Brent A. Neuschwander-Tetri M.D., * Institut National de la Santé et de la Recherche Médicale, Unités Mixtes de Recherche en Santé 893, Hôpital Pitié Salpêtrière, (Assistance Publique Hôpitaux de Paris), Université Pierre et Marie Curie, Paris, France, Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA, Division of Gastroenterology and Hepatology, Saint Louis University, St. Louis, MO.